GROUP
2023 THIRD QUARTER (Jul-Sep)
- Net sales of products
SEK 9 525 (12 180) thousand - Gross profit
SEK 4 517 (7 137) thousand, 47% (59%) - Operating loss
SEK -7 557 (-7 786) thousand - Loss per share
SEK -0,01 (-0,04)
2023 FIRST NINE MONTHS (Jan-Sep)
- Net sales of products
SEK 30 330 (33 442) thousand - Gross profit
SEK 15 603 (19 002) thousand, 51% (57%) - Operating loss
SEK -21 586 (-26 807) thousand - Loss per share -0,02
(-0,12) SEK
Message from our CEO
Sales in
During the third quarter, sales in the important reference market
Increased business flow and new partners
During the third quarter, we continued to make significant progress in our ambition to become a major player in the area of intimate women's health. In August, the merger with
At the same time, we see an upcoming flow of business from our international partners. We have successfully signed a distribution agreement regarding our bacterial vaginosis self-test with
Strong pipeline of new products
During the year, we have focused on developing and in-licensing new products within the framework of our concept Diagnose, Treat, Prevent. The merger with
Shipping delays to
During the third quarter, sales declined as a result of delivery delays to our production unit in
Clear plan going forward for increased sales and profitability
In summary, we expect to see significant improvements from the turn of the year, when the merger with
CEO
9 mon | 9 mon | 12 mon | 12 mon | ||
jan-sep | jan-sep | jan-dec | jan-dec | ||
2023 | 2022 | 2022 | 2021 | ||
Sales goods, KSEK | 30 330 | 33 442 | 43 634 | 31 643 | |
Gross profit sales goods, KSEK | 15 603 | 19 002 | 23 394 | 19 070 | |
Gross margin, % | 51% | 57% | 54% | 60% | |
Operating profit, KSEK | -21 586 | -26 807 | -33 606 | -73 718 | |
Return on equity,% | Negativt | Negativt | Negativt | Negativt | |
Equity ratio,% | 85 | 63 | 55 | 62 | |
Earnings per share, SEK | -0.02 | -0.12 | -0.15 | -0.38 | |
Liquidity per share, SEK | 0.01 | 0.01 | 0.01 | 0.05 | |
Equity per share, SEK | 0.07 | 0.23 | 0.19 | 0.27 | |
Share price per closing, SEK | 0.08 | 0.33 | 0.14 | 0.63 | |
Share price/Equity per share, SEK | 1.23 | 1.42 | 0.72 | 2.30 | |
Equity per share, SEK | 1 175 179 689 | 242 743 544 | 242 743 544 | 191 639 642 | |
FINANCIAL INFORMATION
Group
Revenue - Sales of goods during the third quarter amounted to
The Business Segment Lifestyle has experienced a persistent decline in sales over the past year, resulting in a decrease of
Excluding the delivery delay, the key business area Medical Consumer is growing compared to the same period the previous year. Particularly, the important reference market of
Costs - In the third quarter, costs amounted to
Profit - The group's result after net financial items for the third quarter amounted to
-28,825 thousand in the same period last year.
Financial position and liquidity - Cash and bank as of
Shareholders equity - The group's equity as of
Liabilities - The group's short-term liabilities amounted, as of
Organization - During the period, the average number of employees was 31 (31). At the end of the period, the number of employees amounted to 32 (31).
INCOME STATEMENT | ||||||||
3 mon | 3 mon | 9 mon | 9 mon | 12 mon | ||||
jul-sep | jul-sep | jan-sep | jan-sep | jan-dec | ||||
KSEK | Note | 2023 | 2022 | 2023 | 2022 | 2022 | ||
Operating income | ||||||||
Sales of products | 9 525 | 12 180 | 30 330 | 33 442 | 43 634 | |||
Other operating income | 392 | 187 | 869 | 1 037 | 2 770 | |||
Total operating income | 9 917 | 12 368 | 31 199 | 34 479 | 46 404 | |||
Operating expenses | ||||||||
Cost of goods | -5 008 | -5 043 | -14 727 | -14 440 | -20 239 | |||
Other external expenses | 1 | -6 942 | -7 536 | -21 186 | -26 780 | -34 186 | ||
Personnel costs | -4 678 | -6 081 | -14 345 | -17 337 | -21 922 | |||
Depreciation | -846 | -869 | -2 527 | -2 605 | -3 491 | |||
Other operating costs | 0 | -625 | 0 | -123 | -172 | |||
Total operating expensses | -17 474 | -20 154 | -52 786 | -61 286 | -80 010 | |||
Operating loss | -7 557 | -7 786 | -21 586 | -26 807 | -33 606 | |||
Net financial income | 146 | 0 | 506 | 0 | 0 | |||
Net financial expense | -78 | -738 | -1 863 | -2 019 | -3 251 | |||
Loss before taxes | -7 489 | -8 524 | -22 943 | -28 825 | -36 857 | |||
Taxes | -4 | 0 | -26 | 0 | 0 | |||
Net loss for the period | -7 492 | -8 524 | -22 969 | -28 825 | -36 857 |
BALANCE SHEET | |||||||
30-sep | 30-sep | 31-dec | |||||
KSEK | Note | 2023 | 2022 | 2022 | |||
Assets | |||||||
Non-Current assets | |||||||
Intangeble assets | 2 | 48 556 | 50 447 | 50 098 | |||
Tangeble assets | 4 494 | 4 321 | 4 299 | ||||
Total non-current assets | 53 051 | 54 768 | 54 398 | ||||
Current assets | |||||||
Stock | 18 334 | 17 694 | 15 368 | ||||
Other receivbles | 7 181 | 12 756 | 8 267 | ||||
Tax receivable | 157 | 0 | 89 | ||||
Prepaid expenses and accrued income | 2 386 | 1 432 | 4 064 | ||||
Liquid assets | 8 703 | 3 015 | 3 566 | ||||
Total current assets | 36 762 | 34 898 | 31 354 | ||||
Total assets | 89 812 | 89 666 | 85 752 | ||||
Equity and liabilites | |||||||
Equity | |||||||
Ristricted equity | |||||||
Share capital | 29 379 | 24 274 | 24 274 | ||||
Reserves | 7 392 | 11 186 | 7 392 | ||||
Other contributed capital | 321 720 | 276 157 | 273 613 | ||||
Profit or loss brought forward incl year result | -282 004 | -254 698 | -258 187 | ||||
Total equity | 76 487 | 56 919 | 47 092 | ||||
Current liabilites | |||||||
Liabilities interest bearing | 4 311 | 9 615 | 4 180 | ||||
Trade payables | 5 157 | 16 269 | 22 881 | ||||
Other payables | 1 014 | 992 | 5 720 | ||||
Prepaid income and accrued expenses | 2 843 | 5 872 | 5 879 | ||||
Total current liabilities | 13 325 | 32 747 | 38 660 | ||||
Total equity and liabilities | 89 812 | 89 666 | 85 752 |
Audit
This quarter report has not been subject to be reviewed by the company's auditors.
Assurance
The board and the managing director assure that the year-end report provides a fair overview of the company's operations, position and results.
FINANSIELL KALENDER
Year-end report, 2023 2024-02-23
For more information please contact:
Note: This document has been prepared in both Swedish and English. The Swedish version shall govern in case of differences between the two documents. The document contains certain statements about the Company's operating environment and future performance. These statements should only be regarded as reflective of prevailing interpretations. No guarantees can be made that these statements are free from errors.
About
Peptonic is a Swedish innovative biomedical company that conducts research, development and sales of medical treatments and lifestyle products in the field of women's health. Peptonic has divided its operations into two business areas: "Medical Consumer" and "Lifestyle Consumer". The "Medical Consumer" business area is based on clinically proven intimate self-care and is the company's main focus and is sold under the VagiVital brand. The "Lifestyle Consumer" business area consists of lifestyle products with a focus on menstruation, sex and fertility and is sold under the Lunette brand. The company was founded in 2009 and the share has been traded on Spotlight (www.spotlightstockmarket.com) in
https://news.cision.com/peptonic-medical-ab/r/peptonic-medical-ab--publ-quarterly-report-period-january---september-2023,c3859340
https://mb.cision.com/Main/11203/3859340/2380033.pdf
(c) 2023 Cision. All rights reserved., source